CNBCLean R·
J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion
Johnson & Johnson said it would acquire Ollin for $2.2 billion upfront, with the potential for milestone payments of up to about $1.13 billion.
Read at CNBC →
Johnson & Johnson said it would acquire Ollin for $2.2 billion upfront, with the potential for milestone payments of up to about $1.13 billion.
<iframe src="https://statesidedaily.com/embed/cluster/0a95a7821f7cac222abae970a167b9d273e4ba69" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion"></iframe>